Volume 5.25 | Jul 11 - Prostate Cell News

Prostate Cell News 5.25 July 11, 2014

TOP STORY

How Tumors Remodel Their Surroundings to Grow
A team of scientists from Sanford Burnham Medical Research Institute has found that the loss of a protein called p62 in the cells and tissue surrounding a tumor can enhance the growth and progression of tumors. [Press release from the Sanford Burnham Medical Research Institute discussing online prepublication in Cancer Cell] Press Release | Abstract

FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours

PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Radiotherapy-Induced Plasticity of Prostate Cancer Mobilizes Stem-Like Non-Adherent, Erk Signaling-Dependent Cells
Scientists explored radiation-induced stress response and heterogeneity of human metastatic prostate cancer cells, documented treatment-induced plasticity and phenotypically distinct cell subsets, and suggested the way to exploit their differential sensitivity to radiosensitizing drugs in overcoming radioresistance. [Cell Death Differ] Abstract

Fbxo45-Mediated Degradation of the Tumor-Suppressor Par-4 Regulates Cancer Cell Survival
Investigators demonstrate that Fbxo45 is the substrate-receptor subunit of a functional E3 ligase for prostate apoptosis response protein 4 (Par-4) that has a critical role in cancer cell survival. [Cell Death Differ] Abstract

Androgen Deprivation Induces Phenotypic Plasticity and Promotes Resistance to Molecular Targeted Therapy in a PTEN-Deficient Mouse Model of Prostate Cancer
Researchers used a PTEN-deficient mouse model of prostate cancer to show that plasticity in castration-resistant tumors promotes therapeutic escape. [Carcinogenesis] Abstract

EpCAM Is Overexpressed in Local and Metastatic Prostate Cancer, Suppressed by Chemotherapy and Modulated by MET-Associated miRNA-200c/205
Investigators characterized epithelial cell adhesion molecule (EpCAM) expression on mRNA and protein level in comprehensive tissue studies including non-cancerous prostate specimens, primary tumors of different grades and stages, metastatic lesions, and therapy-treated tumor specimens, as well as in prostate cancer cell lines. [Br J Cancer] Abstract

Combining the Pan-Aurora Kinase Inhibitor AMG 900 with Histone Deacetylase Inhibitors Enhances Antitumor Activity in Prostate Cancer
Researchers used in vitro and in vivo xenograft models of prostate cancer (PCA) to test whether combination of histone deacetylase inhibitors with the pan-aurora kinase inhibitor AMG 900 can synergistically or additively kill PCA cells. [Cancer Med] Full Article

Spheroid Culture of LuCaP 147 as an Authentic Preclinical Model of Prostate Cancer Subtype with SPOP Mutation and Hypermutator Phenotype
Researchers demonstrate capabilities for high-throughput drug screening and that anti-cancer agents induced cell cycle arrest and apoptosis in spheroid cultures, and show that cells formed tumors when re-introduced into mice, providing an authentic in vitro – in vivo preclinical model of a subtype of prostate cancer with a hypermutator phenotype and an SPOP mutation. [Cancer Lett] Abstract

Growth Hormone-Releasing Hormone Antagonists Abolish the Transactivation of Human Epidermal Growth Factor Receptors in Advanced Prostate Cancer Models
The effects of growth hormone-releasing hormone (GHRH) in human epidermal growth factor receptor family members signaling were evaluated on human androgen-independent PC3 prostate cancer cells in vitro and GHRH antagonist in vitro and in nude mice xenografts of PC3 prostate cancer. [Invest New Drugs] Abstract

Krüppel-Like Factor 4 Mediates Lysophosphatidic Acid-Stimulated Migration and Proliferation of PC3M Prostate Cancer Cells
Scientists demonstrate that lysophosphatidic acid stimulates migration and proliferation of highly metastatic human prostate cancer, PC-3M-luc-C6 cells. [Exp Mol Med] Full Article

CLINICAL RESEARCH

Vasectomy and Risk of Aggressive Prostate Cancer: A 24-Year Follow-Up Study
Conflicting reports remain regarding the association between vasectomy, a common form of male contraception in the United States, and prostate cancer risk. Researchers examined prospectively this association with extended follow-up and an emphasis on advanced and lethal disease. [J Clin Oncol] Abstract | Press Release

Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer
Genes of androgen and estrogen signaling and stem cell-like cells have crucial roles in prostate cancer (PC). Scientists aimed to predict clinical failure by estimating these PC-related genes. [Clin Cancer Res] Abstract

REVIEWS

Pathology Consultation on Prostate-Specific Antigen Testing
Authors provide clarity on the pros and cons of using prostate-specific antigen as a screening tool for prostate cancer. [Am J Clin Pathol] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

INDUSTRY NEWS

CIMTEC Announces Spin-Off Company Focal Healthcare, Inc. to Develop the New “Gold Standard” of Targeted Prostate Biopsy and Therapy Devices for the Management of Prostate Cancer
Focal Healthcare was founded as a spin-off company out of the Centre for Imaging Technology Commercialization (CIMTEC). Focal is developing and marketing MRI-Ultrasound Fusion Biopsy and Therapy systems that have strong potential to become the new “gold standard” in prostate care. [CIMTEC]
Press Release

New Grant Enables Humanetics Corporation to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients
Humanetics Corporation has been awarded a grant from the National Cancer Institute to evaluate their proprietary radioprotectant compound, BIO 300, as a potential treatment for erectile dysfunction following prostate cancer radiotherapy. [Humanetics Corporation (Business Wire)] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration) Request your free copy.

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW BIO Latin America 2014
September 9-11, 2014
Rio de Janeiro, Brazil

Visit our events page to see a complete list of events in the prostate cell community.

JOB OPPORTUNITIES

NEW Postdoctoral Fellow – Computational Biology (Netherlands Cancer Institute)

NEW Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

PhD Student – Detection of Novel Prostate Cancer Biomarkers (University of Bath)

Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Cancer Research (Tulane University Health Sciences Center)

Postdoctoral Position – Role of Chromatin in Prostate Cancer (University of Victoria)

Postdoctoral Fellow – Prostate Cancer Research (Henry Ford Hospital)

Research Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Associate – Prostate Cancer Research (Medical University of South Carolina)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development: High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Prostate Cell News: Archives | Events | Contact Us